CML-HSA/Nε-(Carboxymethyl)lysine-HSA

MBL Life Sciences

Shipping:
Calculated at Checkout
$309.00
Adding to cart… The item has been added

Product Description

Reducing sugars react with protein amino groups to form a diverse group of protein-bound moieties with fluorescent and cross-linking properties. These compounds, called advanced glycosylation end products (AGEs), have been implicated in the structural and functional alterations of proteins that occur during aging and long-term diabetes. Although several AGE structures have been reported (1, 2), it was demonstrated that Nε-(Carboxymethyl)lysine (CML) is a major antigenic AGE structure. CML concentration is also increased in patients who have diabetes with complications, including nephropathy (3–5), retinopathy (6), and atherosclerosis (7–9). CML is also recognized by receptor for AGE (RAGE), and CML-RAGE interaction activates cell signaling pathways such as NF-B and enhances the expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells (10).


Documents & Links for CML-HSA/Nε-(Carboxymethyl)lysine-HSA
Datasheet CML-HSA/Nε-(Carboxymethyl)lysine-HSA Datasheet
MSDS CML-HSA/Nε-(Carboxymethyl)lysine-HSA MSDS

Documents & Links for CML-HSA/Nε-(Carboxymethyl)lysine-HSA
Datasheet CML-HSA/Nε-(Carboxymethyl)lysine-HSA Datasheet
MSDS CML-HSA/Nε-(Carboxymethyl)lysine-HSA MSDS